Keyphrases
3-month Follow-up
17%
Adjusted Means
13%
Adjusted Relative Risk
16%
Autoantibodies
17%
Autoimmune
6%
Bayesian Analysis
17%
Bayesian Modeling
5%
Central Nervous System
17%
Cerebrospinal Fluid
23%
Clinically Significant
11%
CNS Complications
11%
Confidence Interval
12%
Coronavirus Disease (COVID)
39%
COVID-19
100%
COVID-19 Complications
17%
Credible Interval
5%
Critical Illness
18%
Days Alive out of Hospital
5%
Days Alive without Life Support
29%
Electronic Health Records
8%
Encephalopathy
11%
EQ-5D
13%
Europe
7%
EuroQol
13%
Health-related Quality of Life
13%
High Dose
7%
High Probability
5%
Hospitalized COVID-19 Patients
11%
India
7%
Intention-to-treat
10%
Intravenous Dexamethasone
7%
Mechanical Ventilation
10%
Mechanically Ventilated Patients
17%
Multicenter Cohort Study
17%
Nervous System Complications
17%
Neurological Symptoms
9%
Neuropsychiatric Symptoms
9%
Number of Days
17%
PaCO2
17%
Patients with COVID-19
7%
Peripheral Nervous System
17%
Population Data
5%
Population-based Cohort Study
17%
Randomized Trial
17%
Sensitivity Analysis
11%
Serious Adverse Reaction
12%
Severe Hypoxemia
52%
Significance Threshold
5%
Tertiary Care Hospital
17%
Visual Analog Scale
13%
Medicine and Dentistry
Brain Disease
5%
Central Nervous System
17%
COVID-19
52%
Critical Illness
11%
Dexamethasone
35%
Hypoxemia
35%
Intention-to-Treat Analysis
8%
Neurotropism
5%
Peripheral Nervous System
17%
Quality of Life
8%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Visual Analog Scale
13%
